GlassScriptPhysician profile
Bradley J Hunter
NPI 1497703581
$4,329.95
in general payments reported to CMS, 2019-2025
35 companies · $760 in 2025
The $760 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $50.70 · 2021: $327 · 2022: $559 · 2023: $1,172 · 2024: $1,143 · 2025: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,075.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $939.19 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $411.64 | 2019-2025 | |
| Lilly USA, LLC | $382.56 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Gilead Sciences, INC. | $266.79 | 2021-2025 | Yeztugo |
| Takeda Pharmaceuticals U.S.A., INC. | $229.42 | 2021-2025 | Trintellix |
| Abbvie INC. | $170.14 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $157.74 | 2022-2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $153.94 | 2019-2024 | Tezspire, Breztri |
| Amgen INC. | $138.37 | 2023-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $132.22 | 2022-2025 | Shingrix, Arexvy |
| Ascensia Diabetes Care US INC. | $123.24 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.99 | 2024-2025 | Relistor, Xifaxan |
| Horizon Therapeutics Plc | $110.50 | 2022 | |
| Exact Sciences Corporation | $107.52 | 2023-2025 | Cologuard Collection Kit |
| Seagen INC. | $99.99 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $97.33 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Novartis Pharmaceuticals Corporation | $91.46 | 2021-2024 | |
| Idorsia Pharmaceuticals US INC | $90.27 | 2023 | Quviviq |
| Sanofi Pasteur INC. | $73.96 | 2023-2024 | |
| Esperion Therapeutics, INC. | $73.13 | 2022-2025 | Nexletol |
| Myriad Women'S Health, INC. | $72.33 | 2023 | Myrisk |
| Merck Sharp & Dohme LLC | $33.19 | 2019-2025 | Capvaxive, Gardasil 9 |
| Biohaven Pharmaceutical Holding Company LTD. | $31.65 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $28.08 | 2019-2020 | |
| Lundbeck LLC | $25.28 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $22.71 | 2023 | Xarelto |
| Astellas Pharma US INC | $22.56 | 2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $21.90 | 2022 | |
| Medtronic, INC. | $17.73 | 2023 | Closurefast |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.67 | 2019 | |
| Daiichi Sankyo INC. | $15.23 | 2021 | |
| Almatica Pharma LLC | $14.18 | 2022 | |
| Seqirus USA INC | $14.08 | 2025 | Fluad, Flucelvax |
| Antares Pharma, INC. | $13.86 | 2022 | |
| Ironwood Pharmaceuticals, INC | $12.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.